Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins
Authors:
Open Access
- 1 January 2018
- Vol. 3 (1) , e000282
Abstract
Background Surgical resection remains the best chance at long-term survival in pancreatic cancer, though margin-positive resections are associated with diminished survival. We examined the effect of margin-positive resection on survival, as well as the role and timing of additional therapies through the National Cancer Database (NCDB). Patients and methods Patients with stage IIA–III pancreatic adenocarcinoma diagnosed from 2004 to 2013 were identified in NCDB. Survival was compared using univariate and multivariate Cox proportional hazards modelling for patients who underwent surgery with negative (R0), microscopically positive (R1) and macroscopically positive (R2) margins or non-surgical treatment. We further analysed patients by margin status, timing of additional therapy (neoadjuvant therapy (NAT) vs adjuvant therapy (AT) vs none) and clinical stage. Results We analysed 44 852 patients. Median survival (MS) for patients who did not undergo surgery was 10.3 months, compared with 19.7 months for R0 (PConclusion R1 resections portend poorer survival than R0 but do not negate the benefit of surgery when additional therapy is given. NAT was associated with improved R0 rates and improved survival for stage III positive-margin patients.Keywords
This publication has 45 references indexed in Scilit:
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative StudyAnnals of Surgical Oncology, 2010
- Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP)HPB, 2009
- Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: Final results of a randomized multi-institutional trialSurgery Today, 2008
- Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins HospitalJournal of Clinical Oncology, 2008
- Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factorBMC Cancer, 2008
- The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United StatesAnnals of Surgical Oncology, 2008
- Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAnnals of Surgery, 2007
- Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival DurationAnnals of Surgical Oncology, 2001
- Resection Margins in Carcinoma of the Head of the PancreasAnnals of Surgery, 1993